Speakers
Professor Paul Kalra Professor of Cardiology, Portsmouth Hospitals NHS Trust, UK
Professor John McMurray Professor of Medical Cardiology, University of Glasgow, UK
Learning objectives
- The main changes in HFrEF therapy in recent years
- The role of SGLT2 inhibitors and MRAs in the management of HFrEF
- Working with patients and healthcare professionals to improve the management of HFrEF
- Management of HFrEF in people with chronic kidney disease
- Management of high-risk HFrEF patients
Learning module instructions
This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning).
Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value.
After you have successfully completed the test you will be able to download your certificate.
Quiz Summary
0 of 5 Questions completed
Questions:
Information
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
Results
Results
0 of 5 Questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Categories
- Not categorized
0%
- 1
- 2
- 3
- 4
- 5
-
Current -
Review -
Answered -
Correct -
Incorrect
-
Question 1 of 5
1. Question
1. Which of the following statements are true regarding “foundational therapy” for HFrEF?
Please select all correct answers.
Correct
Incorrect -
-
Question 2 of 5
2. Question
2. Which of the following qualities of SGLT2 inhibitors make them unique in the management of HFrEF?
Please select all correct answers.
Correct
Incorrect -
-
Question 3 of 5
3. Question
3. Which of the following statements are true about the role of MRAs in the management of HFrEF?
Please select all correct answers.
Correct
Incorrect -
-
Question 4 of 5
4. Question
4. Hospitalisation for HFrEF is a critical opportunity to continue, initiate, and further optimise guideline-directed medical therapy (GDMT).5 However, what percentage of patients are discharged without optimised GDMT?
Please select one answer.
Correct
Incorrect -
-
Question 5 of 5
5. Question
5. Which of the following therapies may be associated with a decline in renal function at initiation?
Please select all correct answers.
Correct
Incorrect -
References
1. McMurray JJV, Docherty KF. Insights into foundational therapies for heart failure with reduced ejection fraction. Clin Cardiol 2022;45 Suppl 1(Suppl 1):S26–S30. https://doi.org/10.1002/clc.23847
2. Shen L, Jhund PS, Docherty KF, et al. Accelerated and personalized therapy for heart failure with reduced ejection fraction. Eur Heart J 2022;43:2573–87. https://doi.org/10.1093/eurheartj/ehac210
3. Zannad F, McMurray JJV, Krum H; EMPHASIS-HF Study Group, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21. https://doi.org/10.1056/nejmoa1009492
4. Matsumoto S, Kondo T, Jhund PS, et al. Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol 2023;82:1080–91. https://doi.org/10.1016/j.jacc.2023.06.021
5. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895–e1032. https://doi.org/10.1161/CIR.0000000000001063
6. Heartfailurematters.org (2023). Aldosterone receptor antagonists or mineralocorticoid receptor antagonist (MRAs). Available at: https://www.heartfailurematters.org/what-your-doctor-can-do/aldosterone-receptor-antagonists-or-mineralocorticoid-receptor-antagonist-mras/#:~:text=What%20they%20do,urine%20and%20are%20weak%20diuretics. (accessed October 2023)
7. National Cardiac Audit Programme (2023). National Heart Failure Audit 2023 Summary Report (2021/22 data). Available at: https://www.nicor.org.uk/wp-content/uploads/2023/10/10633-NICOR-Annual-Summary_Reports_NHFA_AC.pdf (accessed October 2023)
8. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368